Eli Lil­ly, the most talked-about phar­ma­ceu­ti­cal com­pa­ny in re­cent years, is buy­ing can­cer start­up Scor­pi­on Ther­a­peu­tics about half a year af­ter its ...

Eli Lilly & Co. will pay as much as $2.5 billion in cash to acquire a cancer drug that Scorpion Therapeutics Inc. is testing in early and mid-stage trials. The purchase includes an unspecified upfront ...

(Reuters) -Eli Lilly said on Monday it plans to buy Scorpion Therapeutics' experimental cancer therapy for up to $2.5 billion in cash to expand its pipeline of cancer treatments. The company will ...

Eli Lilly will acquire Scorpion's PI3Kα inhibitor STX-478 for ... being evaluated in a Phase 1/2 clinical trial for breast cancer and other advanced solid tumors. Additionally, as part of the ...

Bobby “The Brain” Heenan is widely regarded as one of the greatest ... In January 2002, Bobby Heenan announced that he had been diagnosed with throat cancer. This was a big shock to the wrestling ...

Eli Lilly is reenergizing its attempt to challenge Novartis and Roche for a breast cancer market, kicking off the J.P. Morgan Healthcare Conference with a deal to buy Scorpion Therapeutics ...

SAN FRANCISCO — Eli Lilly said Monday it would acquire a cancer program from startup Scorpion Therapeutics in a deal worth up to $2.5 billion, as the Indianapolis company broadens its pipeline.

Here’s how it works. A new therapy for the most aggressive type of brain cancer can extend patients' survival while cutting the length of treatment. The cancer, glioblastoma, is fast-moving and ...

Jan 13 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Monday it plans to buy Scorpion Therapeutics' experimental cancer therapy for up to $2.5 billion in cash to expand its pipeline of ...